Anti-IFN α and anti-IFN ω autoantibodies are observed in 13% of critically ill COVID-19 patients [98,99,100,101,102,103,104,105], and this percentage increases to 21% in patients older than 80 infected with the virus [98]. The gene discussed is IFNA1; the disease is COVID-19.